At present, NY‐ESO‐1 is the main target of sarcoma immunotherapies in CTAs [30, 47, 59, 65, 66, 67, 68], while there are few studies on MAGE‐A4 [27, 64]. Here, MAGEA4 is linked to sarcoma.